Tarantino, Paolo
Ricciuti, Biagio
Pradhan, Shan M.
Tolaney, Sara M.
Article History
Accepted: 11 May 2023
First Online: 9 June 2023
Competing interests
: P.T. has acted as an adviser and/or consultant of AstraZeneca, Daiichi Sankyo, Gilead and Lilly. B.R. reports fees from Regeneron not related to the present article. S.M.T. has acted as a consultant and/or adviser of 4D Pharma, Aadi Bio, ARC Therapeutics, AstraZeneca, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Gilead, Incyte Corporation, Infinity Therapeutics, Menarini/Stemline, Merck, Myovant, Novartis, Odonate Therapeutics, OncoSec Medical Inc., OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zetagen, and Zymeworks and received research funding from AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Gilead, Genentech/Roche, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Sanofi, and Seattle Genetics. S.M.P. declares no competing interests.